alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I 

111TH CONGRESS 

2D SESSION H. R. 4432 

To direct the Securities and Exchange Commission to revise its reporting 

requirements to require public companies to report certain expenditures 

made to influence public opinion on any matter other than the promotion 

of the company’s products or services. 

IN THE HOUSE OF REPRESENTATIVES 

JANUARY 13, 2010 

Mr. GRAYSON introduced the following bill; which was referred to the 

Committee on Financial Services 

A BILL 

To direct the Securities and Exchange Commission to revise 

its reporting requirements to require public companies 

to report certain expenditures made to influence public 

opinion on any matter other than the promotion of the 

company’s products or services. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Corporate Propaganda 

5 Sunshine Act’’. 


jbell on DSKDVH8Z91PROD with BILLS
2 

•HR 4432 IH

1 SEC. 2. REPORTING OF EXPENDITURES. 

2 Not later than 30 days after the date of enactment 

3 of this Act, the Securities and Exchange Commission shall 

4 revise its regulations issued pursuant to sections 13 and 

5 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 

6 78m and 78o(d)) to require that issuers include in the re7 ports required under those sections any expenditure or se8 ries of expenditures of the issuer totaling $1,000 or more 

9 made for the purpose of influencing public opinion on any 

10 matter other than the promotion of the issuer’s products 

11 or services. Such disclosures shall include the date, 

12 amount, and purpose of the expenditure and identify (by 

13 name, address, and phone number) the person to whom 

14 it was made. 

Æ 


jbell on DSKDVH8Z91PROD with BILLS
Case: 1:07-cr-00137-MHW Doc #: 67 Filed: 02/27/12 Page: 1 of 1  PAGEID #: 248
Dolan Chemical Laboratory

4001 Bixby Road

Groveport, OH 43125

T: 614-836-4221, Audinet 210-4221

F: 614-836-4168, Audinet 210-4168

http://aepenv/labs

Water Analysis

Location: Mountaineer Plant Report Date: 3/8/2012

Sample Number: 120961-001 Date Collected: 02/29/2012 08:00 Date Received: 2/29/2012

1st Stage Feed 

Parameter Result Units RL MDL Analysis By Analysis Date/Time Method

Selenium, Se 384 ug/L 0.5 0.1 DPC 03/06/2012 11:43 EPA 200.8

Sample Number: 120961-002 Date Collected: 02/29/2012 08:00 Date Received: 2/29/2012

2nd Stage Feed 

Parameter Result Units RL MDL Analysis By Analysis Date/Time Method

Selenium, Se 27.0 ug/L 0.5 0.1 DPC 03/06/2012 11:48 EPA 200.8

Sample Number: 120961-003 Date Collected: 02/29/2012 08:00 Date Received: 2/29/2012

Bioreactor Effluent 

Parameter Result Units RL MDL Analysis By Analysis Date/Time Method

Selenium, Se 1.99 ug/L 0.5 0.1 DPC 03/06/2012 11:53 EPA 200.8

THIS TEST REPORT RELATES ONLY TO THE ITEMS TESTED AND SHALL NOT BE REPRODUCED EXCEPT IN FULL WITHOUT WRITTEN 

APPROVAL OF THE LABORATORY. ALL TEST RESULTS MEET ALL OF THE REQUIREMENTS OF THE ACCREDITING AUTHORITY, 

UNLESS OTHERWISE NOTED.

Brian Snyder, Chemist II

Email bssnyder@aep.com Tel. 614-836-4224

Fax 614-836-4168 Audinet 210-4224

Mountaineer Plant, 120961 Page 1 of 1
Key Terms of Compensation Arrangements for Named Executive Officers



 Exhibit 10.54 

KEY TERMS OF COMPENSATION ARRANGEMENTS FOR 

NAMED EXECUTIVE OFFICERS FOR FISCAL 2010 

The named executive officers of The Gymboree Corporation (the “Company”) each receive an annual salary, are eligible to participate in the
Company’s annual Bonus Plan, equity compensation plan and 401K plan, and receive medical, dental and vision insurance benefits. They are also eligible for benefits under the Company’s Amended and Restated Management Change of Control Plan,
including a payment equal to a multiple of annual compensation (as specified below), and benefits under the Company’s Amended and Restated Management Severance Plan, including a severance payment equal to 100% of base salary. Individual
compensation terms for the Company’s 2010 fiscal year are set forth below. 
  

										
	 Name and Principal Position
	  	Base
Salary	  	Target
Bonus

Payout*	 	 	Change
of
Control
Multiple**	 
	 Matthew K. McCauley
	  	$	637,500	  	150	% 	 	300	% 
	 Chairman and CEO
	  			  			 		
				
	 Blair W. Lambert
	  	$	338,800	  	85	% 	 	300	% 
	 COO
	  			  			 		
				
	 Kip M. Garcia
	  	$	374,000	  	100	% 	 	300	% 
	 President
	  			  			 		
				
	 Marina Armstrong
	  	$	338,800	  	85	% 	 	300	% 
	 SVP, General Manager and Secretary
	  			  			 		
				
	 Jeffrey P. Harris
	  	$	285,000	  	65	% 	 	300	% 
	 CFO
	  			  			 		
				
	 Lynda G. Gustafson
	  	$	207,000	  	40	% 	 	200	% 
	 VP, Corporate Controller
	  			  			 		

  

	*	Designated as a percentage of base salary. The plan maximum for Ms. Gustafson is 150% of target bonus payout. 


	**	Designated as a percentage of base salary and average bonus for prior three full fiscal years.
COURT OF APPEALS

EIGHTH DISTRICT OF TEXAS

EL PASO, TEXAS

IN THE INTEREST OF: J.A., JR.,

A MINOR CHILD. §

§

§

§

§

§ No. 08

- 1 3

- 00253

- CV

Appeal from

233rd District Court

of Tarrant County, Texas

(TC # 233

- 484891

- 10)

CORRECTED JUDGMENT

The Court has considered this cause on the record and concludes there was no error in the

judgment. We therefore affirm the judgment of the court below. We further order that Appellee

recover from Appellant and its sureties, if any, see T EX .R.A PP .P. 43.5 , on the judgment and all

costs, both in this Court and the court below for which let execution issue. This decision shall be

certified below for observance.

IT IS SO ORDERED THIS 2 1ST DAY OF AUGUST, 2015.

ANN CRAWFORD McCLURE, Chief Justice

Before McClure, C.J., Rodriguez, and Hughes, JJ.
IN THE UNITED STATES DISTRICT COURT

FOR THE SOUTHERN DISTRICT OF OHIO

WESTERN DIVISION

Daniel P. Hargrove, :

:

Plaintiff(s), :

: Case Number: 1:17cv748

vs. :

: Judge Susan J. Dlott

Capt. Frisby, et al., :

:

Defendant(s). :

ORDER

The Court has reviewed the Report and Recommendation of United States Magistrate Judge

Stephanie K. Bowman filed on January 11, 2018 (Doc. 10), to whom this case was referred pursuant to

28 U.S.C. §636(b), and noting that no objections have been filed thereto and that the time for filing

such objections under Fed. R. Civ. P. 72(b) expired January 25, 2018, hereby ADOPTS said Report and

Recommendation.

Accordingly, plaintiff’s complaint (Doc. 1) is DISMISSED with prejudice pursuant to 28

U.S.C. §§1915(e)(2)(B) and 1915A(b)(1) with the exception of plaintiff’s Fourth Amendment

individual capacity claim against defendants Frisby and Couch and plaintiff’s First Amendment

individual capacity Free Exercise claim and, to the extent it seeks injunctive relief, plaintiff’s Religious

Land Use and Institutionalized Persons Act (RLUIPA) claim against defendants Chaplain Taylor and

Chaplain Palmer.

Plaintiff’s motion to add a defendant (Doc. 7) is DENIED.

IT IS SO ORDERED.

___s/Susan J. Dlott___________

Judge Susan J. Dlott

United States District Court
Exhibit 99.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In  connection  with the  Quarterly  Report of Quintek  Technologies,  Inc. (the
"Company")  on Form 10-QSB for the period  ending March 31, 2003,  as filed with
the Securities and Exchange Commission on the date hereof (the "Report"), Robert
Steele,  Chief  Executive  Officer of the Company,  certifies to the best of his
knowledge,  pursuant to 18 U.S.C.  Sec. 1350, as adopted pursuant to Sec. 906 of
the Sarbanes-Oxley Act of 2002, that:

      (1) The Report fully  complies with the  requirements  of Section 13(a) or
  15(d) of the Securities Exchange Act of 1934; and

      (2) The  information  contained  in the  Report  fairly  presents,  in all
  material  respects,  the  financial  condition and result of operations of the
  Company.


/s/ ROBERT STEELE
----------------------------
    Robert Steele
    Chief Executive Officer

May 15,  2003

The foregoing  certification  is being  furnished  solely  pursuant to 18 U.S.C.
Sec.1350  and is  not  being  filed  as  part  of the  Report  or as a  separate
disclosure document.
Case: 3:17-mj-00442-SLO Doc #: 1 Filed: 09/21/17 Page: 1 of 10 PAGEID #: 1
Case: 3:17-mj-00442-SLO Doc #: 1 Filed: 09/21/17 Page: 2 of 10 PAGEID #: 2
Case: 3:17-mj-00442-SLO Doc #: 1 Filed: 09/21/17 Page: 3 of 10 PAGEID #: 3
Case: 3:17-mj-00442-SLO Doc #: 1 Filed: 09/21/17 Page: 4 of 10 PAGEID #: 4
Case: 3:17-mj-00442-SLO Doc #: 1 Filed: 09/21/17 Page: 5 of 10 PAGEID #: 5
Case: 3:17-mj-00442-SLO Doc #: 1 Filed: 09/21/17 Page: 6 of 10 PAGEID #: 6
Case: 3:17-mj-00442-SLO Doc #: 1 Filed: 09/21/17 Page: 7 of 10 PAGEID #: 7
Case: 3:17-mj-00442-SLO Doc #: 1 Filed: 09/21/17 Page: 8 of 10 PAGEID #: 8
Case: 3:17-mj-00442-SLO Doc #: 1 Filed: 09/21/17 Page: 9 of 10 PAGEID #: 9
Case: 3:17-mj-00442-SLO Doc #: 1 Filed: 09/21/17 Page: 10 of 10 PAGEID #: 10
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM UNAUDITED
CONDENSED CONSOLIDATED BALANCE SHEETS AND STATEMENTS OF OPERATIONS AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>                     <C>
<PERIOD-TYPE>                   9-MOS                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-2000             DEC-31-2000
<PERIOD-START>                             JAN-01-2000             JAN-01-1999
<PERIOD-END>                               SEP-30-2000             DEC-31-1999
<CASH>                                         197,005                  80,023
<SECURITIES>                                         0                       0
<RECEIVABLES>                                   16,218                     163
<ALLOWANCES>                                         0                       0
<INVENTORY>                                     51,362                   9,649
<CURRENT-ASSETS>                               272,747                  95,627
<PP&E>                                          37,737                   5,315
<DEPRECIATION>                                   8,839                   2,806
<TOTAL-ASSETS>                                 310,484                 100,942
<CURRENT-LIABILITIES>                           22,522                   8,681
<BONDS>                                              0                       0
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                          0                       8
<COMMON>                                            13                       3
<OTHER-SE>                                     287,286                  91,717
<TOTAL-LIABILITY-AND-EQUITY>                   310,484                 100,942
<SALES>                                         29,498                   3,034
<TOTAL-REVENUES>                                29,498                   3,034
<CGS>                                           20,845                   1,032
<TOTAL-COSTS>                                   20,845                   1,032
<OTHER-EXPENSES>                               123,144                  49,195
<LOSS-PROVISION>                                   618                   1,367
<INTEREST-EXPENSE>                                  31                     153
<INCOME-PRETAX>                              (108,630)                (46,570)
<INCOME-TAX>                                         2                       2
<INCOME-CONTINUING>                          (108,632)                (46,572)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                 (112,874)                (46,572)
<EPS-BASIC>                                     (1.01)                  (2.58)
<EPS-DILUTED>                                   (1.01)                  (2.58)


</TABLE>
Exhibit 21.1

Subsidiaries of Zoran Corporation



|                                          |  |                             
|----------------------------------------- |  | ----------------------------
|Name                                      |  | Jurisdiction of Registration
|Zoran Digital Technologies (Shenzhen) Ltd |  | China                       
|Zoran GmbH                                |  | Germany                     
|Zoran Microelectronics Ltd.               |  | Israel                      
|Zoran Japan K.K.                          |  | Japan                       
|Zoran Korea Ltd.                          |  | South Korea                 
|Zoran Asia Pacific Ltd.                   |  | Hong Kong                   
|Zoran UK Ltd.                             |  | United Kingdom              
|Zoran Electronics Singapore Pte. Ltd.     |  | Singapore                   
|Zoran International, Inc.                 |  | Delaware, U.S.A.            
|Oak Technology, LLC                       |  | Delaware, U.S.A.            
|Pixel Magic, Inc.                         |  | Delaware, U.S.A             
|Zoran France SA                           |  | France                      
|Microtune, (GP) L.L.C.                    |  | Delaware                    
|Microtune, (LP) L.L.C.                    |  | Delaware                    
|Microtune (Texas), L.P.                   |  | Texas                       
|Microtune (San Diego), Inc.               |  | California                  
|HMTF Acquisition (Bermuda) Ltd.           |  | Bermuda                     
|HMTF Erste Beteilingungs GmbH             |  | Germany                     
|Microtune Verwaltungs GmbH                |  | Germany                     
|Microtune GmbH & Co. KG                   |  | Germany                     
|Microtune (Japan), Inc.                   |  | Delaware                    
|Transilica Singapore Pte Ltd              |  | Singapore                   
|Microtune (Taiwan), Ltd.                  |  | Taiwan                      
|Microtune (Korea), Ltd.                   |  | Korea                       
|Microtune RF-Technologies (Phil.), Inc.   |  | Philippines                 
|NSF-Technologies (Phil.), Inc.            |  | Philippines                 
|Auvitek International Ltd.                |  | Cayman Islands              
|Auvitek Corporation                       |  | Delaware                    
|Microtune Shanghai, Ltd.                  |  | China                       
|Microtune (Hong Kong) Limited             |  | Hong Kong
Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 1 of 14  PAGEID #: 1

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 2 of 14  PAGEID #: 2

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 3 of 14  PAGEID #: 3

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 4 of 14  PAGEID #: 4

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 5 of 14  PAGEID #: 5

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 6 of 14  PAGEID #: 6

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 7 of 14  PAGEID #: 7

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 8 of 14  PAGEID #: 8

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 9 of 14  PAGEID #: 9

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 10 of 14  PAGEID #: 10

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 11 of 14  PAGEID #: 11

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 12 of 14  PAGEID #: 12

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 13 of 14  PAGEID #: 13

Case: 2:17-mj-00723-KAJ Doc #: 1 Filed: 12/04/17 Page: 14 of 14  PAGEID #: 14
EXHIBIT 23.1**CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**     We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos.333-4318, 333-86155, 333-86159, 333-45288, 333-63036, 333-91996, 333-106698, and 333-117133) ofMolecular Devices Corporation of our reports dated March 15, 2007, with respect to the consolidatedfinancial statements and schedule of Molecular Devices Corporation, Molecular Devices Corporationmanagement’s assessment of the effectiveness of internal control over financial reporting and theeffectiveness of internal control over financial reporting of Molecular Devices Corporation,included in this Annual Report (Form 10-K) for the year ended December 31, 2006./s/ Ernst & Young LLPPalo Alto, California
Page 1 of 3

Disposition Comments

Docket No: FAA-2011-0911 These comments are in

Directorate ID: 2010-NM-248-AD response to an SNPRM

Originating Office Tracking No.: 

Next Step: FRAN SNPRM

 No Comments/Only Supportive Comments Received – If this box is checked, no signatures are 

required.

No Has the referenced service information been revised since the NPRM was issued? If yes, 

list latest revision and attach a copy. Note that changes beyond the scope of the previously 

published NPRM will require a new notice. Contact the Directorate focal point for guidance.

Instructions: Summarize all comments by issue (not by commenter) and provide your recommended resolution of 

each issue. All comments relating to the same issue should be discussed together. Do not list all of the issues 

from one commenter together. If changes to the AD are required based on the comments received, explain why and 

describe in detail what change(s) you recommend. Reference FAA-IR-M-8040.1C Chapter 9.

ISSUE 1: Select one of the following: 

If other, explain: 

Commenter(s): 

What change to the AD action is requested? 

Why is the change requested or how is it justified? 

Do we agree? 

If YES, we agree because Make the following changes to the AD: 

If PARTIALLY AGREE, we agree with because We disagree with because 

Make the following changes to the AD: 

If NO, we don’t agree because 

ISSUE 2: Select one of the following: 

If other, explain: 

Commenter(s): 

What change to the AD action is requested? 

Why is the change requested or how is it justified? 

Do we agree? 

If YES, we agree because Make the following changes to the AD: 

If PARTIALLY AGREE, we agree with because We disagree with because 

Make the following changes to the AD:
Page 2 of 3

If NO, we don’t agree because 

For additional issues, double-click here
Page 3 of 3

Signature Section

Signature indicates concurrence with this action.

Originating Office Tracking No.: 

ASE Printed Name: Date

Branch Manager Date
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Mental Health Special Emphasis Panel; Instrumentation Program (S10 Clinical Trial Not Allowed).                    

*Date:*                         February 14, 2022.                    

*Time:*                         11:00 a.m. to 2:00 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                              ( print page 2170)    

*Place:*                         National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call).                    

*Contact Person:*                         Evon S. Ereifej, Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, Rockville, MD 20852,                         *ereifejes@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)

Dated: January 7, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-00524 Filed 1-12-22; 8:45 am]

BILLING CODE 4140-01-P
<PAGE>
                                                                    EXHIBIT 23.1

               CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

      We consent to the incorporation by reference in the Registration
Statements (Form S-8 No. 333-86155, 333-86159, 333-45288, 333-63036 and
333-91996 pertaining to the LJL BioSystems, Inc. 1994 Equity Incentive Plan, LJL
BioSystems, Inc. 1997 Stock Plan, LJL BioSystems, Inc. 1998 Directors' Stock
Option Plan, 1995 Stock Option Plan, 1995 Non-Employee Directors' Stock Option
Plan, 1995 Employee Stock Purchase Plan and 2001 Stock Option Plan of Molecular
Devices Corporation of our report dated January 27, 2003, with respect to the
consolidated financial statements and schedule of Molecular Devices Corporation
included in the Annual Report (Form 10-K) for the year ended December 31, 2002.

                                                           /s/ Ernst & Young LLP

Palo Alto, California
March 25, 2003


                                       1